Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy‐free, first‐line treatment for PD‐L1‐positive non‐small cell lung cancer
Abstract Background Nivolumab plus ipilimumab (N‐I) or pembrolizumab (PEM) is associated with survival improvement as chemotherapy‐free, first‐line treatment for patients with advanced non‐small cell lung carcinoma (NSCLC) and positive programmed cell death ligand 1 (PD‐L1). However, no direct compa...
Main Authors: | Yixin Zhou, Yaqiong Zhang, Guifang Guo, Xiuyu Cai, Hui Yu, Yanyu Cai, Bei Zhang, Shaodong Hong, Li Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-03-01
|
Series: | Clinical and Translational Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/ctm2.14 |
Similar Items
-
An Indirect Comparison Between Nivolumab + Ipilimumab + Two Cycles of Chemotherapy vs. Pembrolizumab + Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer
by: Panpan Jiang, et al.
Published: (2021-09-01) -
Nivolumab plus Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis
by: Koichi Ando, et al.
Published: (2020-07-01) -
Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis
by: Abdulaali R. Almutairi, et al.
Published: (2020-02-01) -
Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
by: Bin Wu, et al.
Published: (2018-11-01) -
Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
by: Justin C. Moser, et al.
Published: (2019-12-01)